Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18889398 | METHODS AND KITS USEFUL FOR DIAGNOSIS OF HUMAN PAPILLOMAVIRUS (HPV) | September 2024 | February 2025 | Allow | 4 | 2 | 0 | No | No |
| 18629820 | INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE | April 2024 | July 2024 | Allow | 3 | 0 | 0 | No | No |
| 18431303 | SELECTIVE 3-PRENYL 5-METHYL ETHER, 7-O-RHAMNOSIDE FLAVONE FOR THE TREATMENT OF HEPATIC CANCER | February 2024 | September 2024 | Allow | 7 | 1 | 0 | No | No |
| 18391316 | COMBINATION THERAPY FOR HIV WITH ADENOSINE DERIVATIVE AND CAPSID INHIBITORS | December 2023 | January 2025 | Allow | 13 | 1 | 0 | No | No |
| 18522134 | METHODS AND COMPOSITIONS FOR TREATMENT OF COVID-19 | November 2023 | February 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18377979 | Nicotinyl Riboside Compounds and Their Uses | October 2023 | September 2024 | Allow | 11 | 1 | 0 | No | No |
| 18471764 | ADMINISTRATION OF NICOTINAMIDE MONONUCLEOTIDE IN THE TREATMENT OF DISEASE | September 2023 | August 2024 | Allow | 10 | 0 | 0 | No | No |
| 18244693 | METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) | September 2023 | November 2024 | Allow | 15 | 1 | 0 | No | No |
| 18463313 | METHODS FOR ISOLATING TARGET ANALYTES FROM BIOLOGICAL SAMPLES USING ATPS AND SOLID PHASE MEDIA | September 2023 | June 2024 | Allow | 10 | 2 | 0 | No | No |
| 18237503 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | August 2023 | October 2024 | Allow | 14 | 1 | 0 | Yes | No |
| 18232896 | Methods for Treating HCV | August 2023 | December 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18225452 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | July 2023 | October 2024 | Allow | 15 | 1 | 0 | No | No |
| 18345903 | TLR7 AGONISTS | June 2023 | July 2024 | Allow | 12 | 0 | 0 | No | No |
| 18339082 | METHODS AND SYSTEMS FOR NUCLEIC ACID PREPARATION AND CHROMATIN ANALYSIS | June 2023 | December 2024 | Allow | 17 | 2 | 0 | No | No |
| 18309435 | 2'-DEOXY-2',2'-DIFLUOROTETRAHYDROURIDINES WITH HIGH PURITY AND METHODS OF MAKING THE SAME | April 2023 | September 2024 | Allow | 17 | 3 | 0 | No | No |
| 18307733 | METHODS OF PREPARING NICOTINAMIDE RIBOSIDE AND DERIVATIVES THEREOF | April 2023 | January 2025 | Allow | 21 | 1 | 0 | Yes | No |
| 18306662 | NUTRITIONAL FORMULATIONS INCLUDING HUMAN MILK OLIGOSACCHARIDES AND ANTIOXIDANTS AND USES THEREOF | April 2023 | January 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18187463 | 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | March 2023 | July 2024 | Allow | 16 | 1 | 0 | No | No |
| 18157449 | LINKER STRUCTURES WITH MINIMAL SCAR FOR ENZYMATIC SYNTHESIS | January 2023 | September 2024 | Allow | 20 | 1 | 0 | No | No |
| 17904536 | COMBINATION DECITABINE AND CEDAZURIDINE SOLID ORAL DOSAGE FORMS | August 2022 | October 2024 | Allow | 26 | 1 | 0 | No | No |
| 17766074 | 2'-DEOXY-2',2'-DIFLUOROTETRAHYDROURIDINES WITH HIGH PURITY AND METHODS OF MAKING THE SAME | April 2022 | August 2024 | Allow | 29 | 1 | 0 | No | No |
| 17532182 | Fusion Albumin Nanoparticle and Application Thereof | November 2021 | January 2025 | Allow | 38 | 0 | 0 | No | No |
| 17608780 | Crosslinked Nucleoside Intermediate Crystal And Method For Producing Same, And Method For Producing Crosslinked Nucleoside Amidite | November 2021 | August 2024 | Allow | 34 | 0 | 0 | No | No |
| 17447344 | TREATMENT AND PREVENTION OF NEISSERIA GONORRHOEAE INFECTION USING CMP-ACTIVATED NONULOSONATE ANALOG COMPOUNDS | September 2021 | July 2024 | Allow | 35 | 0 | 0 | No | No |
| 17433257 | OPHTHALMIC COMPOSITION CONTAINING DIQUAFOSOL OR SALT THEREOF, VINYL-BASED POLYMER AND CELLULOSE-BASED POLYMER | August 2021 | December 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17414946 | ANTICANCER COMPOUNDS | June 2021 | September 2024 | Allow | 39 | 1 | 0 | No | No |
| 17238182 | COMPOSITION FOR TREATING BLOOD CANCER USING 4'-THIO-5-AZA-2'-DEOXYCYTIDINE AND USES THEREOF | April 2021 | September 2024 | Allow | 41 | 3 | 0 | Yes | Yes |
| 17273988 | METHOD FOR PRODUCING GLYCOSIDE COMPOUND | March 2021 | May 2024 | Allow | 38 | 1 | 0 | No | No |
| 17253448 | MITOCHONDRIAL NUCLEIC ACID DEPLETION AND DETECTION | December 2020 | July 2024 | Allow | 43 | 1 | 1 | No | No |
| 17051931 | SEGMENT FOR USE IN SYNTHESIS OF OLIGONUCLEOTIDE, METHOD FOR PRODUCING THE SAME, AND METHOD FOR SYNTHESIZING OLIGONUCLEOTIDE USING THE SAME | October 2020 | July 2024 | Allow | 44 | 2 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LEWIS, PATRICK T.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner LEWIS, PATRICK T works in Art Unit 1693 and has examined 9 patent applications in our dataset. With an allowance rate of 88.9%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 39 months.
Examiner LEWIS, PATRICK T's allowance rate of 88.9% places them in the 70% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by LEWIS, PATRICK T receive 1.00 office actions before reaching final disposition. This places the examiner in the 8% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by LEWIS, PATRICK T is 39 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +14.3% benefit to allowance rate for applications examined by LEWIS, PATRICK T. This interview benefit is in the 53% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 50.0% of applications are subsequently allowed. This success rate is in the 96% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 100.0% of cases where such amendments are filed. This entry rate is in the 98% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 88% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 0% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 4% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.